Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Purpose To investigate whether the blood-brain barrier (BBB) leaks blood-circulating substances in patients with early forms of Alzheimer disease (AD), and if so, to examine the extent and pattern of leakage. Materials and Methods This study was approved by the local medical ethical committees of the Maastricht University Medical Center and Leiden University Medical Center, and written informed consent was obtained from all subjects. For this pilot study, 16 patients with early AD and 17 healthy age-matched control subjects underwent dynamic contrast material–enhanced magnetic resonance (MR) imaging sequence with dual time resolution for 25 minutes. The Patlak graphical approach was used to quantify the BBB leakage rate and local blood plasma volume. Subsequent histogram analysis was used to determine the volume fraction of the leaking brain tissue. Differences were assessed with linear regression analysis, adjusted for confounding variables. Results The BBB leakage rate was significantly higher in patients compared with that in control subjects in the total gray matter (P < .05) and cortex (P = .03). Patients had a significantly higher volume fraction of the leaking brain tissue in the gray matter (P = .004), normal-appearing white matter (P < .04), deep gray matter (P = .01), and cortex (P = .004). When all subjects were considered, scores on the Mini-Mental State Examination decreased significantly with increasing leakage in the deep gray matter (P = .007) and cortex (P < .05). Conclusion The results of this study showed global BBB leakage in patients with early AD that is associated with cognitive decline. A compromised BBB may be part of a cascade of pathologic events that eventually lead to cognitive decline and dementia. ©RSNA, 2016 Online supplemental material is available for this article. An earlier incorrect version of this article appeared online. This article was corrected on October 24, 2016.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent neuroimaging studies in individuals with mild cognitive impairment (MCI) and early AD reveal BBB breakdown in the hippocampus, including its CA1 and dentate gyrus subfields (421), and several gray and white matter regions (220-222), respectively, before brain atrophy and dementia.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BBB leakiness is seen both with normal ageing and AD [124,125].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [125]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the BBB disruption and increased permeability have been shown to occur in the early phase of the AD pathology (van de Haar et al., 2016).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as van de Haar et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Research works printed but not linked: 1
- Butman J, 2006, Proceedings of the Fourteenth Meeting of the International Society for Magnetic Resonance in Medicine, 1535
Cited by
Items 201–300 of 653
Methods used for the measurement of blood-brain barrier integrity
Sun, H., Hu, H., Liu, C., Sun, N., & Duan, C. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00694-8 · Cited by 54
Lipids and lipoproteins may play a role in the neuropathology of Alzheimer’s disease
Akyol, Ö., Akyol, S., Chou, M., Chen, S., Liu, C., Selek, S., Soares, J. C., & Chen, C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1275932 · Cited by 53
French, S. R., Meyer, B. P., Arias, J. C., Levendovszky, S. R., & Weinkauf, C. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70104 · Cited by 53
Ohene, Y., Harrison, I. F., Evans, P., Thomas, D. L., Lythgoe, M. F., & Wells, J. A. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28496 · Cited by 53
Zhao, Q., Dai, W., Chen, H. Y., Jacobs, R. E., Zlokovic, B. V., Lund, B. T., Montagne, A., & Bonnin, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113310119 · Cited by 52
Bacterial Extracellular DNA Promotes β-Amyloid Aggregation
Tetz, G. V., & Tetz, V. (2021) · Microorganisms · doi:10.3390/microorganisms9061301 · Cited by 52
Novel insights into RIPK1 as a promising target for future Alzheimer’s disease treatment
Li, S., Qu, L., Wang, X., & Kong, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107979 · Cited by 52
Aβ1-42 induces cell damage via RAGE-dependent endoplasmic reticulum stress in bEnd.3 cells
Chen, W., Chan, Y., Wan, W., Li, Y., & Zhang, C. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.005 · Cited by 51
Endothelial Progenitor Cells and Vascular Alterations in Alzheimer’s Disease
Custodia, A., Ouro, A., Romaus-Sanjurjo, D., Pías-Peleteiro, J. M., de Vries, H. E., Castillo, J., & Sobrino, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.811210 · Cited by 43
Wyatt-Johnson, S. K., & Brutkiewicz, R. R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.592359 · Cited by 50
Alzheimer’s Disease: A Systems View Provides a Unifying Explanation of Its Development
Grobler, C., van Tongeren, M., Gettemans, J., Kell, D. B., & Pretorius, E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220720 · Cited by 51
Glymphatic System Dysfunction in Central Nervous System Diseases and Mood Disorders
Zhang, D., Li, X., & Li, B. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.873697 · Cited by 49
The Effects of Long-Term Saturated Fat Enriched Diets on the Brain Lipidome
Giles, C., Takechi, R., Mellett, N. A., Meikle, P. J., Dhaliwal, S. S., & Mamo, J. C. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166964 · Cited by 49
Wong, S. M., Jansen, J. F. A., Zhang, C. E., Staals, J., Hofman, P. A. M., van Oostenbrugge, R. J., Jeukens, C. R. L. P. N., & Backes, W. H. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25540 · Cited by 49
Self-citationImaging blood–brain barrier disruption in neuroinflammation and Alzheimer’s disease
Lee, R., & Funk, K. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1144036 · Cited by 48
Huang, P., & Zhang, M. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00905-x · Cited by 47
Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease
D'Cunha, N. M., McKune, A. J., Panagiotakos, D. B., Georgousopoulou, E. N., Thomas, J., Mellor, D. D., & Naumovski, N. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1349032 · Cited by 47
The multiple roles of chronic stress and glucocorticoids in Alzheimer's disease pathogenesis
Burke, M. R., Sotiropoulos, I., & Waites, C. L. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.015 · Cited by 46
APOE 𝜀4‐related blood–brain barrier breakdown is associated with microstructural abnormalities
Reas, E. T., Solders, S. K., Tsiknia, A. A., Triebswetter, C., Shen, Q., Rivera, C. S., Andrews, M., Alderson‐Myers, A., & Brewer, J. B. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14302 · Cited by 46
The validity of 18F-GE180 as a TSPO imaging agent
Zanotti‐Fregonara, P., Veronese, M., Pascual, B., Rostomily, R., Turkheimer, F., & Masdeu, J. C. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-4268-4 · Cited by 46
“For instance, numerous imaging and postmortem studies have shown that Alzheimer’s disease is associated with BBB leakage [23, 24].”
Dickie, B., Boutin, H., Parker, G. J. M., & Parkes, L. M. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4510 · Cited by 46
Sources of systematic error in DCE‐MRI estimation of low‐level blood‐brain barrier leakage
Manning, C., Stringer, M. S., Dickie, B., Clancy, Ú., Hernández, M. C. V., Wiseman, S. J., García, D. J., Sakka, E., Backes, W. H., Ingrisch, M., et al. (2021) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28833 · Cited by 46
Self-citationKok, F. K., van Leerdam, S., & de Lange, E. C. M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-210607 · Cited by 46
Yin, C., Zhang, M., Jin, S., Zhou, Y., Ding, L., Lv, Q., Huang, Z., Zhou, J., Chen, J., Wang, P., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155725 · Cited by 45
Claudin-5 and occludin levels in patients with psychiatric disorders − A systematic review
Maridaki, Z., Syrros, G., Delichatsiou, S. G., Warsh, J. J., & Konstantinou, G. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.11.006 · Cited by 46
Pericytes: Problems and Promises for CNS Repair
Laredo, F., Plebanski, J., & Tedeschi, A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00546 · Cited by 44
van Dinther, M., Voorter, P., Jansen, J. F. A., Jones, E. A. V., van Oostenbrugge, R. J., Staals, J., & Backes, W. H. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221076557 · Cited by 44
Self-citationGustafsson, S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund-Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 44
“Imaging studies also imply subtle BBB impairment in patients with mild cognitive impairment and early stages of AD, even before the manifestation of brain atrophy and dementia (4-6).”
Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease
Schröder, N., Schaffrath, A., Welter, J. A., Putzka, T., Griep, A., Ziegler, P., Brandt, E., Samer, S., Heneka, M. T., Kaddatz, H., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01816-2 · Cited by 43
Freeze, W. M., Schnerr, R. S., Palm, W. M., Jansen, J. F., Jacobs, H. I., Hoff, E. I., Verhey, F. R., & Backes, W. H. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5273 · Cited by 43
Self-citationJana, A., Wang, X., Leasure, J. W., Magana, L., Wang, L., Kim, Y.-M., Dodiya, H., Toth, P. T., Sisodia, S. S., & Rehman, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-20889-y · Cited by 43
The Role of Heparin and Glycocalyx in Blood–Brain Barrier Dysfunction
Yang, R., Chen, M., Zheng, J., Li, X., & Zhang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754141 · Cited by 44
Clinical magnetic resonance imaging evaluation of glymphatic function
Boyd, E., Kaur, J., Ding, G., Chopp, M., & Jiang, Q. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5132 · Cited by 43
Gulej, R., Nyúl‐Tóth, Á., Csík, B., Patai, R., Petersen, B., Negri, S., Chandragiri, S. S., Shanmugarama, S., Mukli, P., Yabluchanskiy, A., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01154-8 · Cited by 44
Gustafsson, S. S., Lindström, V., Ingelsson, M., Hammarlund‐Udenaes, M., & Syvänen, S. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.002 · Cited by 43
Zhang, W., Xiong, B., Zhang, L., Huang, X., Zhou, W., Zou, Q., Manyande, A., Wang, J., Tian, X., & Tian, Y. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13388 · Cited by 43
Robust Multi-TE ASL-Based Blood–Brain Barrier Integrity Measurements
Mahroo, A., Buck, M. A., Huber, J., Breutigam, N.-J., Mutsaerts, H. J. M. M., Craig, M., Chappell, M. A., & Günther, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.719676 · Cited by 43
Saeliw, T., Permpoon, T., Iadsee, N., Tencomnao, T., Hu, V. W., Sarachana, T., GREEN, D. J., & Sae‐Lee, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-18232-6 · Cited by 43
Vascular risk burden is a key player in the early progression of Alzheimer’s disease
Ferrari‐Souza, J. P., Brum, W. S., Hauschild, L. A., Ros, L. U. D., Ferreira, P. C. L., Bellaver, B., Leffa, D. T., Bieger, A., Tissot, C., Lussier, F. Z., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.12.008 · Cited by 43
Muszyński, P., Kulczyńska-Przybik, A., Borawska, R., Litman-Zawadzka, A., Słowik, A., Klimkowicz-Mrowiec, A., Pera, J., Dziedzic, T., & Mroczko, B. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170220 · Cited by 38
Postsynaptic Proteome of Non-Demented Individuals with Alzheimer’s Disease Neuropathology
Zolochevska, O., Bjorklund, N., Woltjer, R., Wiktorowicz, J. E., & Taglialatela, G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180179 · Cited by 42
Kim, S., Sharma, C., Jung, U. J., & Kim, S. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051383 · Cited by 43
Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review
Ulanova, M., Poljak, A., Wen, W. X., Bongers, A., Gloag, L., Gooding, J. J., Tilley, R. D., Sachdev, P. S., & Braidy, N. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0316 · Cited by 42
Ha, I. H., Lim, C., Kim, Y., Moon, Y., Han, S., & Moon, W. (2021) · Korean Journal of Radiology · doi:10.3348/kjr.2020.0816 · Cited by 42
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
Liu, L., Wang, N., Kalionis, B., Xia, S., & He, Q. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577763 · Cited by 41
AT1 Receptors: Their Actions from Hypertension to Cognitive Impairment
Wu, H., Sun, Q., Yuan, S., Wang, J., Li, F., Gao, H., Chen, X., Yang, R., & Xu, J. (2022) · Cardiovascular Toxicology · doi:10.1007/s12012-022-09730-0 · Cited by 41
Lü, L., Huang, L., Wang, L., Wu, Y., Chen, Z., & Liu, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.775244 · Cited by 41
Padovani, A., Galli, A., Bazzoli, E., Tolassi, C., Caratozzolo, S., Gumina, B., Benussi, A., Libri, I., Outeiro, T. F., & Pilotto, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14556 · Cited by 40
Lahiri, S., Regis, G. C., Koronyo, Y., Fuchs, D.-T. S., Sheyn, J., Kim, E. H., Mastali, M., Eyk, J. E. V., Rajput, P. S., Lyden, P. D., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2356-2 · Cited by 40
Dobric, A., Luca, S. N. D., Spencer, S. J., Bozinovski, S., Saling, M. M., McDonald, C. F., & Vlahos, R. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108017 · Cited by 40
When the infectious environment meets the AD brain
Ganz, T., Fainstein, N., & Ben-Hur, T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00559-3 · Cited by 39
DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study
Keil, V. C., Gielen, G. H., Pintea, B., Baumgarten, P., Datsi, A., Hittatiya, K., Simon, M., & Hattingen, E. (2021) · Clinical Neuroradiology · doi:10.1007/s00062-021-01015-3 · Cited by 39
Ma, C., Wu, Y., Song, L., Yin, L., Yin, J.-J., Wang, Q., Yu, J., & Xiao, B. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355747 · Cited by 39
“However, imaging detection in the early stage of AD indicates BBB disruption, initially focused in certain gray and white matter sites (Montagne et al., 2016; van de Haar et al., 2016).”
BackgroundMontagne, A., Huuskonen, M. T., Rajagopal, G., Sweeney, M. D., Nation, D. A., Sepehrband, F., D'Orazio, L. M., Harrington, M. G., Chui, H. C., Law, M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.012 · Cited by 32
Polyphenols Bioactive Metabolites, and Their Anti-Biofilm and Neuroprotective Potential
Nazzaro, F., Coppola, F., Fratianni, F., Abdalrazeq, M., Ombra, M. N., Giulio, B. D., Coppola, R., & Zengin, G. (2025) · Foods · doi:10.3390/foods14223976 · Cited by 38
Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer’s Disease
Tao, Q., Lin, R.-R., Chen, Y.-H., & Wu, Z. (2022) · Aging and Disease · doi:10.14336/ad.2022.0130-1 · Cited by 38
Moussiopoulou, J., Yakimov, V., Roell, L., Rauchmann, B., Toth, H., Melcher, J., Jäger, I. M., Lutz, I., Kallweit, M. S., Papazov, B., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.003 · Cited by 37
Preininger, M. K., Zaytseva, D., Lin, J. M., & Kaufer, D. (2023) · Aging Cell · doi:10.1111/acel.13747 · Cited by 36
“…of individuals with mild cognitive impairment (MCI) (Montagne et al., 2015; Wang et al., 2006) and occurs before hippocampal atrophy in AD (van de Haar et al., 2016; Van De Haar et al., 2016), suggesting hippocampal BBBD may be critical early step towards neurodegeneration (Montagne et…”
BackgroundStringer, M. S., Lee, H., Huuskonen, M. T., MacIntosh, B. J., Brown, R., Montagne, A., Atwi, S., Ramirez, J., Jansen, M. A., Marshall, I., et al. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00843-8 · Cited by 36
Tzekaki, E. E., Papaspyropoulos, A., Tsolaki, M., Lazarou, E., Kozori, M., & Pantazaki, Α. A. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111178 · Cited by 36
Singh, C. S. B., Choi, K. B., Munro, L., Wang, H. Y., Pfeifer, C. G., & Jefferies, W. A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103503 · Cited by 36
“Finally, BBB leakage first noted in this model [7,10,12,14] has recently been proposed as an early biomarker in patients with AD [38,39].”
BackgroundMagnetic Resonance Imaging in Animal Models of Alzheimer’s Disease Amyloidosis
Ni, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312768 · Cited by 37
Aquilani, R., Ramusino, M. C., Maestri, R., Iadarola, P., Boselli, M., Perini, G., Boschi, F., Dossena, M., Bellini, A., Buonocore, D., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1237469 · Cited by 36
Kim, Y. S., Kim, M., Choi, S. H., You, S., Yoo, R., Kang, K. M., Yun, T. J., Lee, S., Moon, J., & Shin, Y. (2019) · Radiology · doi:10.1148/radiol.2019182566 · Cited by 35
Unzeta, M., Hernández‐Guillamón, M., Sun, P., & Solé, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073365 · Cited by 35
Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01398-5 · Cited by 35
Cortical cerebrovascular and metabolic perturbations in the 5xFAD mouse model of Alzheimer’s disease
Jullienne, A., Szu, J. I., Quan, R., Trinh, M. V., Norouzi, T., Noarbe, B. P., Bedwell, A. A., Eldridge, K., Persohn, S. A., Territo, P. R., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1220036 · Cited by 35
Neurovascular dysfunction in dementia – human cellular models and molecular mechanisms
Parkes, I., Chintawar, S., & Cader, M. Z. (2018) · Clinical Science · doi:10.1042/cs20160720 · Cited by 35
Khadka, N., & Bikson, M. (2020) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13338 · Cited by 34
Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?
Rodríguez-Jiménez, F. J., Ureña‐Peralta, J. R., Jendelová, P., & Erceg, S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.01.006 · Cited by 34
Taoka, T., Ito, R., Nakamichi, R., Nakane, T., Kawai, H., & Naganawa, S. (2022) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.rev.2022-0012 · Cited by 33
Age-Associated mRNA and miRNA Expression Changes in the Blood-Brain Barrier
Goodall, G., Leach, V., Wang, C., Cooper‐Knock, J., Heath, P. R., Baker, D., Drew, D. R., Saffrey, M. J., Simpson, J. E., Romero, I. A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123097 · Cited by 33
“demonstrated that dysfunction of the BBB is a feature of ageing [10], mild cognitive impairment and early AD [11,12].”
BackgroundInterleukin-17A in Alzheimer’s Disease: Recent Advances and Controversies
Yan, X.-Z., Lai, L., Ao, Q., Tian, X.-H., & Zhang, Y.-H. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210823110004 · Cited by 32
Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging
Albano, D., Bruno, F., Agostini, A., Angileri, S. A., Benenati, M., Bicchierai, G., Cellina, M. I., Chianca, V., Cozzi, D., Danti, G., et al. (2021) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01223-4 · Cited by 32
Akushevich, I. V., Yashkin, A. P., Kravchenko, J. S., Ukraintseva, S. V., Stallard, E., & Yashin, A. I. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180060 · Cited by 31
“Moreover, new diagnostic approaches such as the tests for blood-brain barrier leakage [41] and other innovations [42] may increase the proportion of diagnoses of early AD among patients both before and after onset of MCI.”
Lin, Z., Jiang, D., Liu, D., Li, Y., Uh, J., Hou, X., Pillai, J. J., Qin, Q., Ge, Y., & Lu, H. (2021) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28687 · Cited by 31
Lloret, A., Esteve, D., Lloret, M.-Á., Monllor, P., López, B., Leon, J. L. A., & Cervera‐Ferri, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.708061 · Cited by 31
Guarnieri, L., Bosco, F., Leo, A., Citraro, R., Palma, E., Sarro, G. D., & Mollace, V. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102210 · Cited by 30
Unveiling the hidden connection: the blood-brain barrier’s role in epilepsy
Han, J., Wang, Y., Wei, P., Lu, D., & Shan, Y. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1413023 · Cited by 30
Morgan, C., Thomas, D. L., Shao, X., Mahroo, A., Manson, T. J., Suresh, V., Jansson, D., Ohene, Y., Günther, M., Wang, D. J. J., et al. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5256 · Cited by 30
Reddan, J. M., White, D., Macpherson, H., Scholey, A. B., & Pipingas, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00049 · Cited by 30
Madsen, L. S., Nielsen, R. B., Parbo, P., Ismail, R., Mikkelsen, I. K., Gottrup, H., Østergaard, L., Brooks, D. J., & Eskildsen, S. F. (2022) · Aging Brain · doi:10.1016/j.nbas.2022.100035 · Cited by 30
“Breakdown of the BBB has been shown to occur early in the development of AD and other neurodegenerative diseases [48].”
BackgroundBlood–brain barrier leakage years after pre‐eclampsia: dynamic contrast‐enhanced 7‐Tesla MRI study
Canjels, L. P. W., Jansen, J. F. A., Alers, R., Ghossein‐Doha, C., van den Kerkhof, M., Schiffer, V. M. M. M., Mulder, E., Gerretsen, S. C., Aldenkamp, A. P., Hurks, P. P. M., et al. (2022) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.24930 · Cited by 30
Self-citationChe, P., Zhang, J., Yu, M., Tang, P., Wang, Y., Lin, A., Xu, J., & Zhang, N. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14112 · Cited by 30
Function and therapeutic value of astrocytes in diabetic cognitive impairment
Meng, F., Fu, J., Zhang, L., Guo, M., Zhuang, P., Yin, Q., & Zhang, Y. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105591 · Cited by 31
Alzheimer’s Disease: From Amyloid to Autoimmune Hypothesis
Arshavsky, Y. I. (2020) · The Neuroscientist · doi:10.1177/1073858420908189 · Cited by 30
Verheggen, I. C. M., de Jong, J. J. A., van Boxtel, M. P. J., Postma, A. A., Verhey, F. R. J., Jansen, J. F. A., & Backes, W. H. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00228-x · Cited by 29
Self-citationMoon, Y., Jeon, H. J., Han, S., Noh, M., Kim, H.-J., Kwon, K. J., Moon, W., & Kim, S. H. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231180035 · Cited by 29
Acidifying Endolysosomes Prevented Low-Density Lipoprotein-Induced Amyloidogenesis
Liang, H., Soliman, M. L., Geiger, N. H., Miller, N., Afghah, Z., Lakpa, K. L., Chen, X., & Geiger, J. D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180941 · Cited by 29
Nagano, H., Ito, S., Masuda, T., & Ohtsuki, S. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03131-8 · Cited by 29
Distinct effects of cholesterol profile components on amyloid and vascular burdens
Kang, S. H., Yoo, H., Cheon, B. K., Park, Y. H., Kim, S.-J., Ham, H., Jang, H., Kim, H. J., Oh, K., Koh, S., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01342-2 · Cited by 28
Blood-brain barrier biomarkers
Zapata-Acevedo, J. F., Mantilla-Galindo, A., Vargas-Sánchez, K., & González-Reyes, R. E. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.04.004 · Cited by 28
Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective
Lam, V., Hackett, M. J., & Takechi, R. (2016) · Nutrients · doi:10.3390/nu8120828 · Cited by 28
Macdonald, D. W., Berdoy, M., & Webster, J. P. (2015) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780198745501.003.0011 · Cited by 27
Dynamic Contrast-Enhanced MRI and Its Applications in Various Central Nervous System Diseases
Kim, K. J., Park, M., Joo, B., Ahn, S. J., & Suh, S. H. (2022) · Investigative Magnetic Resonance Imaging · doi:10.13104/imri.2022.26.4.256 · Cited by 27
Hergert, D. C., Gaasedelen, O. J., Ryman, S. G., Prestopnik, J., Caprihan, A., & Rosenberg, G. A. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034225 · Cited by 27
A Microfluidic Human Model of Blood–Brain Barrier Employing Primary Human Astrocytes
Lauranzano, E., Campo, E., Rasile, M., Molteni, R., Pizzocri, M., Passoni, L., Bello, L., Pozzi, D., Pardi, R., Matteoli, M., et al. (2019) · Advanced Biosystems · doi:10.1002/adbi.201800335 · Cited by 27
Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease
Fülöp, T., Tripathi, S., Rodrigues, S., Desroches, M., Bunt, T., Eiser, A. R., Bernier, F., Beauregard, P. B., Barron, A. E., Khalil, A., et al. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264910 · Cited by 27
Bakhtiari, A., Vestergaard, M. B., Benedek, K., Fagerlund, B., Mortensen, E. L., Osler, M., Lauritzen, M., Larsson, H. B. W., & Lindberg, U. (2022) · GeroScience · doi:10.1007/s11357-022-00712-2 · Cited by 26
Metadata
- Authors
- van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H.
- Affiliations
- Maastricht University Medical Centre (NL)
- Leiden University Medical Center (NL)
- Leiden University (NL)
- ORCID
- Venue
- Radiology
- Published
- 2016-11
- Volume
- 281
- Issue
- 2
- Pages
- 527-535
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2415637550
- Cited by
- 601
- References
- 32
- Citations by year
- 2026: 37 · 2025: 56 · 2024: 66 · 2023: 65 · 2022: 81 · 2021: 89 · 2020: 64 · 2019: 50 · 2018: 42 · 2017: 36 · 2016: 13
- FWCI
- 25.63
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Radiology (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- Radiological Society of North America
- Internationale Stichting Alzheimer Onderzoek (10553)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- blood-brain barrier disruption, early Alzheimer's disease, dynamic contrast-enhanced MRI, Patlak graphical analysis, plasma volume, gray matter, normal-appearing white matter, deep gray matter, cognitive decline, Mini-Mental State Examination
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Blood Volume, Blood-Brain Barrier, Contrast Media, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pilot Projects, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.